EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alternative substitutions of N332 in HIV-1 AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan

Jeffy Jeffy, Durgadevi Parthasarathy, Shamim Ahmed, Héctor Cervera-Benet, Ulahn Xiong, Miranda Harris, Dmitriy Mazurov, Stephanie Pickthorn, Alon Herschhorn iD

mBio · 2024

DOI: 10.1128/mbio.02686-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Jeffy Jeffy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV Seropositivity, HIV-1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The envelope glycoprotein (Env) trimer on the surface of human immunodeficiency virus type I (HIV-1) mediates viral entry into host CD4 + T cells and is the sole target of neutralizing antibodies. Broadly neutralizing antibodies (bnAbs) that target gp120 V3-glycan of HIV-1 Env trimer are potent and block the entry of diverse HIV-1 strains. Most V3-glycan bnAbs interact, to a different extent, with a glycan attached to N332, but Asn at this position is not absolutely conserved or required for HIV-1 entry based on the prevalence of N332 in different circulating HIV-1 strains from diverse clades. Here, we studied the effects of amino acid changes at position 332 of HIV-1 AD8 Envs on HIV-1 sensitivity to antibodies, cold exposure, and soluble CD4. We further investigated how these changes affect Env function and HIV-1 infectivity in vitro . Our results suggest robust tolerability of HIV-1 AD8 Env N332 to changes, with specific changes that resulted in extended exposure of gp120 V3 loop, which is typically concealed in most primary HIV-1 isolates. Viral evolution leading to Asn at position 332 of HIV AD8 Envs is supported by the selection advantage of high levels of cell–cell fusion, transmission, and infectivity with high levels of cell surface expression and slightly higher gp120 shedding than most N332 variants. Thus, tolerance of HIV-1 AD8 Envs to different amino acids at position 332 provides increased flexibility to respond to changing conditions/environments and evade the immune system. Modeling studies of the distance between N332 glycan and specific bnAbs were in agreement with N332 glycan dependency on bnAb neutralization. Overall, our studies provide insights into the contribution of specific amino acids at position 332 to Env antigenicity, stability on ice, and conformational states. IMPORTANCE Glycan attached to amino acid asparagine at position 332 of HIV-1 envelope glycoproteins is a main target of a subset of broadly neutralizing antibodies that block HIV-1 infection. Here, we defined the contribution of different amino acids at this position to Env antigenicity, stability on ice, and conformational states.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV SeropositivityHIV-1HumansAmino AcidsAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusGlycoproteinsHIV AntibodiesHIV Envelope Protein gp120IcePolysaccharides

Stichwörter der Autor:innen

V3-glycanbroadly neutralizing antibodiesfitnesshuman immunodeficiency virus

Substanzen

Amino AcidsAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusGlycoproteinsHIV AntibodiesHIV Envelope Protein gp120IcePolysaccharidesgp120 protein, Human immunodeficiency virus 1

Autor:innen und Institutionen

  • Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Institute for Engineering in Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Center of Genomic Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
  • Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, Minnesota, USA.
  • The College of Veterinary Medicine Graduate Program, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Alon Herschhorn

Förderung

  • NIAID NIH HHS
  • NIGMS NIH HHS
  • NIDA NIH HHS
  • HHS | NIH | National Institute on Drug Abuse
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Jeffy, J., Parthasarathy, D., Ahmed, S., Cervera-Benet, H., Xiong, U., Harris, M., Mazurov, D., Pickthorn, S., & Herschhorn, A. (2024). Alternative substitutions of N332 in HIV-1 AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan. mBio. https://doi.org/10.1128/mbio.02686-23

Vancouver

Jeffy J, Parthasarathy D, Ahmed S, Cervera-Benet H, Xiong U, Harris M, et al. Alternative substitutions of N332 in HIV-1 AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan. mBio. 2024. doi:10.1128/mbio.02686-23

BibTeX
@article{Jeffy2024,
  author = {Jeffy, Jeffy and Parthasarathy, Durgadevi and Ahmed, Shamim and Cervera-Benet, Héctor and Xiong, Ulahn and Harris, Miranda and Mazurov, Dmitriy and Pickthorn, Stephanie and Herschhorn, Alon},
  title = {Alternative substitutions of N332 in HIV-1 AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.02686-23}
}
Kostenlos starten →